Nonadherence to cardiovascular medication is exceptionally
common and results in preventable morbidity, mortality,
and health spending (1). Reducing patient copayments for
highly effective, evidence-based therapies has been proposed as a
method of stimulating greater adherence that may also reduce
health spending (2). This strategy has been met with particular